real-time news and commentary for investors
Tuesday, Dec 18
2012, 12:17 PM
Arrowhead Research (ARWR -6.8%) says it's signed a research collaboration and license agreement...
Arrowhead Research (ARWR -6.8%) says it's signed a research collaboration and license agreement with Shire (SHPG +0.8%) to develop and commercialize targeted peptide-drug conjugates by utilizing ARWR's human-derived Homing Peptide platform and SHPG's therapeutic payloads. Arrowhead will receive research funding and could be eligible for milestone payments of up to $32.8M for each development candidate, plus additional milestone payments for a second indication, as well as royalties on worldwide sales.